LHRH agonists vs hormone receptor positive breast cancer

Analyses focused on women with tumours positive for oestrogen receptor, progesterone receptor, or both have shown that LHRH ( luteinising-hormone-releasing hormone ) agonists did not significantly reduce recurrence, when used as the only systemic adjuvant treatment, Addition of LHRH agonists to tamoxifen, chemotherapy, or both reduced recurrence .
And LHRH agonists were ineffective in hormone-receptor-negative tumours.